Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
- Author(s)
- Wu, MY; Shepherd, STC; Fendler, A; Carr, EJ; Au, L; Harvey, R; Dowgier, G; Hobbs, A; Herman, LS; Ragno, M; Adams, L; Schmitt, AM; Tippu, Z; Shum, B; Farag, S; Rogiers, A; O'Reilly, N; Bawumia, P; Smith, C; Carlyle, E; Edmonds, K; Del Rosario, L; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Korteweg, J; Foley, T; Barber, T; Hepworth, S; Emslie-Henry, A; Caulfield-Lynch, N; Byrne, F; Deng, D; Williams, B; Brown, M; Caidan, S; Gavrielides, M; MacRae, JI; Kelly, G; Peat, K; Kelly, D; Murra, A; Kelly, K; O'Flaherty, M; Popat, S; Yousaf, N; Jhanji, S; Tatham, K; Cunningham, D; Van As, N; Young, K; Furness, AJS; Pickering, L; Beale, R; Swanton, C; Gandhi, S; Gamblin, S; Bauer, DLV; Kassiotis, G; Howell, M; Walker, S; Nicholson, E; Larkin, J; Wall, EC; Turajlic, S; CAPTURE Consortium;
- Details
- Publication Year 2023-05-08,Volume 41,Issue #5,Page 821-823
- Journal Title
- Cancer Cell
- Publication Type
- Correspondence
- Abstract
- Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
- Publisher
- Cell Press
- Keywords
- Humans; *covid-19; SARS-CoV-2; *Hematologic Neoplasms/drug therapy; *Neoplasms
- Department(s)
- Medical Oncology
- PubMed ID
- 37116490
- Publisher's Version
- https://doi.org/10.1016/j.ccell.2023.04.005
- Open Access at Publisher's Site
- https://doi.org/10.1016/j.ccell.2023.04.005
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-05 06:33:38
Last Modified: 2023-09-05 06:34:32